Anti-reflux Surgery for Lung Transplant Recipients in the Presence of Impedance-detected Duodenogastroesophageal Reflux and Bronchiolitis Obliterans Syndrome: a Study of Efficacy and Safety
Overview
Authors
Affiliations
Background: The aim of this study was to determine the safety of anti-reflux surgery for lung transplant recipients and assess its effect on lung function.
Methods: We retrospectively collected and analyzed data from all lung transplant recipients who underwent anti-reflux surgery at St Mary's Hospital London from July 2005 to May 2012. The indications for surgery were histologic evidence of gastroesophageal reflux aspiration on bronchoscopy biopsy specimens or a positive impedance study with symptomatic reflux or a consistent decline/fluctuating forced expiratory volume in 1 second (FEV(1)). We studied the difference in mean FEV(1) and rate of change of FEV(1), before and after fundoplication. The safety of anti-reflux surgery was determined by post-operative morbidity and mortality and compared with predicted figures, using a risk prediction model based on the P-POSSUM (Portsmouth Modification of the Physiological and Operative Severity Score for Enumeration of Mortality and Morbidity) assessment.
Results: Forty patients underwent laparoscopic Nissen fundoplication. Overall, mean FEV(1) declined from 2119 ± 890 to 1967 ± 1027 ml (p = 0.027), and mean rate of change in FEV(1) improved from -2.42 ± 4.40 to -0.41 ± 1.77 ml/day (p = 0.007). Patients referred for fundoplication based on histologic evidence of reflux (n = 9) showed an improvement in rate of change of FEV(1) from -3.39 ± 6.00 to -0.17 ± 1.50 ml/day (p = 0.057), and those with positive impedance study and consistent decline in FEV(1) (n = 13) showed a significant improvement from -3.62 ± 3.35 to -0.74 ± 2.33 ml (p = 0.021). Actual and predicted morbidity was 2.5% and 31%, respectively. Actual and predicted 30-day mortality was 0% and 1.9%, respectively.
Conclusions: Anti-reflux surgery is safe for lung transplant recipients and results in an improvement in the rate of change in FEV(1) despite a decline in mean FEV(1) post-operatively.
Krahelski O, Ali I, Namgoong C, Dave K, Reed A, Ashrafian H Surg Endosc. 2024; 39(1):19-38.
PMID: 39586876 PMC: 11666770. DOI: 10.1007/s00464-024-11392-8.
Wu R, Robayo V, Nguyen D, Chan E, Chihara R, Huang H Surg Endosc. 2024; 38(4):2134-2141.
PMID: 38443500 DOI: 10.1007/s00464-024-10719-9.
Elsheikh M, Akanbi L, Selby L, Ismail B J Neurogastroenterol Motil. 2023; 30(2):156-165.
PMID: 38062800 PMC: 10999846. DOI: 10.5056/jnm23017.
Decreased Lymphocytic Bronchitis Severity in the Era of Azithromycin Prophylaxis.
Santos J, Hays S, Golden J, Calabrese D, Kolaitis N, Kleinhenz M Transplant Direct. 2023; 9(9):e1495.
PMID: 37575951 PMC: 10414707. DOI: 10.1097/TXD.0000000000001495.
Lo W, Flanagan R, Sharma N, Goldberg H, Chan W World J Transplant. 2023; 13(4):138-146.
PMID: 37388387 PMC: 10303416. DOI: 10.5500/wjt.v13.i4.138.